Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells

European Journal of Pharmaceutical Sciences

Volumn 47, Issue 4, 2012, Pages 686-694

  Minelli, Rosalba ^a,b   Cavalli, Roberta ^a   Ellis, Leigh ^b   Pettazzoni, Piergiorgio ^a,b   Trotta, Francesco ^a   Ciamporcero, Eric ^a   Barrera, Giuseppina ^a   Fantozzi, Roberto ^a   Dianzani, Chiara ^a   Pili, Roberto ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cyclodextrin nanosponge; Androgen receptor; Camptothecin; DNA damage; DNA Topoisomerase I; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; BETA CYCLODEXTRIN; CAMPTOTHECIN; DNA TOPOISOMERASE; LIPOCORTIN 5; PROPIDIUM IODIDE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; CAMPTOTHECIN; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; DNA DAMAGE; DRUG CARRIERS; HISTONES; HUMANS; MALE; NANOSTRUCTURES; PARTICLE SIZE; PHOSPHORYLATION; PROSTATIC NEOPLASMS; SOLUBILITY; TOPOISOMERASE I INHIBITORS;

EID: 84866489239     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.08.003     Document Type: Article

References (41)

1. D.J. Bharali, M. Khalil, M. Gurbuz, T.M. Simone, and S.A. Mousa Nanoparticles and cancer therapy: a concise review with emphasis on dendrimers Int. J. Nanomed. 4 2009 1 7
2. G. Brandi, G. Biasco, M.G. Mirarchi, R. Golfieri, A. Di Paolo, A. Borghi, S. Fanello, E. Derenzini, V. Agostini, E. Giampalma, A. Cappelli, P. Pini, S. Costantini, R. Danesi, L. Bolondi, and F. Piscaglia A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma Digest. Liver Dis. 43 2011 1015 1021
3. H.A. Burris 3rd., A. Awada, J.G. Kuhn, J.R. Eckardt, P.W. Cobb, D.A. Rinaldi, S. Fields, L. Smith, and D.D. Von Hoff Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion Anticancer Drugs 5 1994 394 402
4. R. Cavalli, F. Trotta, and W. Tumiatti Cyclodextrin-based nanosponges for drug delivery J. Incl. Phenom. Macrocycl. Chem. 56 2006 209 213
5. M.E. Davis The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic Mol. Pharm. 6 2009 659 668
6. J.P. Droz, and A. Chaladaj Management of metastatic prostate cancer: the crucial role of geriatric assessment BJU Int. 101 Suppl 2 2008 23 29
7. B.J. Feldman, and D. Feldman The development of androgen-independent prostate cancer Nat. Rev. Cancer 1 2001 34 45
8. A. Hayashi, H. Suzuki, K. Itoh, M. Yamamoto, and Y. Sugiyama Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts Biochem. Biophys. Res. Commun. 310 2003 824 829
9. K. Hayashi, H. Kuniyasu, N. Oue, H. Shigeishi, K. Kuraoka, H. Nakayama, and W. Yasui Induction of hRAD9 is required for G2/M checkpoint signal transduction in gastric cancer cells Pathobiology 70 2002 40 46
10. R.P. Hertzberg, M.J. Caranfa, and S.M. Hecht On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex Biochemistry 28 1989 4629 4638
11. X.X. Huang, C.L. Zhou, H. Wang, C. Chen, S.Q. Yu, Q. Xu, Y.Y. Zhu, and Y. Ren Pharmacokinetics, efficacy, and safety evaluation of docetaxel/ hydroxypropyl-sulfobutyl-β-cyclodextrin inclusion complex AAPS PharmSciTech. 12 2011 665 672
12. C.B. Jones, M.K. Clements, S. Wasi, and S.S. Daoud Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest Cancer Chemother. Pharmacol. 45 2000 252 258
13. Y. Kageyama, N. Hyochi, K. Kihara, and H. Sugiyama The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer Recent Pat. Anticancer Drug Discov. 2 2007 203 211
14. O.M. Koo, I. Rubinstein, and H. Onyuksel Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine Nanomedicine 1 2005 77 84
15. S. Kummar, M. Raffeld, L. Juwara, Y. Horneffer, A. Strassberger, D. Allen, S.M. Steinberg, A. Rapisarda, S.D. Spencer, W.D. Figg, X. Chen, I.B. Turkbey, P. Choyke, A.J. Murgo, J.H. Doroshow, and G. Melillo Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors Clin. Cancer Res. 17 2011 5123 5513
16. M.K. Kwak, and T.W. Kensler Targeting NRF2 signaling for cancer chemoprevention Toxicol. Appl. Pharmacol. 244 2010 66 76
17. K. Legarza, and L.X. Yang New molecular mechanisms of action of camptothecin-type drugs Anticancer Res. 26 2006 3301 3305
18. S. Liu, Y. Yuan, Y. Okumura, N. Shinkai, and H. Yamauchi Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth Biochem. Biophys. Res. Commun. 394 2010 297 302
19. C. Massard, and K. Fizazi Targeting continued androgen receptor signaling in prostate cancer Clin. Cancer Res. 17 2011 3876 3883
20. M.M. Nguyen, and Z. Wang Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer Minerva Urol. Nefrol. 60 2008 15 29
21. T. Nguyen, P.J. Sherratt, and C.B. Pickett Regulatory mechanisms controlling gene expression mediated by the antioxidant response element Annu. Rev. Pharmacol. Toxicol. 43 2003 233 260
22. T. Nguyen, C.S. Yang, and C.B. Pickett The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress Free Radic. Biol. Med. 37 2004 433 441
23. J.H. Park, K.H. Choi, and H.S. Kwak Single- and 14-day repeat-dose toxicity of cross-linked β-cyclodextrin in rats Int. J. Toxicol. 30 2011 700 706
24. P. Pettazzoni, E. Ciamporcero, C. Medana, S. Pizzimenti, Bello.F. Dal, V.G. Minero, C. Toaldo, R. Minelli, K. Uchida, M.U. Dianzani, R. Pili, and G. Barrera Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells Free Radical Biol. Med. 51 2011 1610 1618
25. H.C. Pitot, R.M. Goldberg, J.M. Reid, J.A. Sloan, P.A. Skaff, C. Erlichman, J. Rubin, P.A. Burch, A.A. Adjei, S.A. Alberts, L.J. Schaaf, G. Elfring, and L.L. Miller Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy Clin. Cancer Res. 6 2000 2236 2244
26. Y. Pommier Topoisomerase I inhibitors: camptothecins and beyond Nat. Rev. Cancer 6 2006 789 802
27. N.M. Reddy, S.R. Kleeberger, M. Yamamoto, T.W. Kensler, C. Scollick, S. Biswal, and S.P. Reddy Genetic dissection of the Nrf2-dependent redox signaling-regulated transcriptional programs of cell proliferation and cytoprotection Physiol. Genomics. 32 2007 74 81
28. N. Sharifi New agents and strategies for the hormonal treatment of castration-resistant prostate cancer Expert Opin. Inv. Drugs 19 2010 837 846
29. M.M. Shen, and C. Abate-Shen Molecular genetics of prostate cancer: new prospects for old challenges Genes Dev. 24 2010 1967 2000
30. S. Swaminathan, P.R. Vavia, F. Trotta, and S. Torne Formulation of betacyclodextrin based nanosponges of itraconazole J. Incl. Phenom. Macrocycl. Chem. 57 2007 89 94
31. S. Swaminathan, L. Pastero, L. Serpe, F. Trotta, P. Vavia, D. Aquilano, M. Trotta, G. Zara, and R. Cavalli Cyclodextrin-based nanosponges encapsulating camptothecin: physicochemical characterization, stability and cytotoxicity Eur. J. Pharm. Biopharm. 74 2010 193 201
32. P. Takahashi, A. Polson, and D. Reisman Elevated transcription of the p53 gene in early S-phase leads to a rapid DNA-damage response during S-phase of the cell cycle Apoptosis 16 2011 950 958
33. M.E. Taplin Drug insight: role of the androgen receptor in the development and progression of prostate cancer Nat. Clin. Pract. Oncol. 4 2007 236 244
34. S. Torne, S. Darandale, P. Vavia, F. Trotta, and R. Cavalli Cyclodextrin-based nanosponges: effective nanocarrier for tamoxifen delivery Pharm. Dev. Technol. 2012 (Epub ahead of print)
35. S.J. Torne, K.A. Ansari, P.R. Vavia, F. Trotta, and R. Cavalli Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges Drug Deliv. 17 2010 419 425
36. F. Trotta, and R. Cavalli Characterization and applications of new hyper-cross-linked cyclodextrins Compos. Interfaces 16 2009 39 48
37. V.J. Venditto, and E.E. Simanek Cancer therapies utilizing the camptothecins: a review of the in vivo literature Mol. Pharm. 7 2010 307 349
38. M.E. Wall, M.C. Wani, C.E. Cook, K.H. Palmer, A.T. McPhail, and G.A. Sim Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca accuminata J. Am. Chem. Soc. 88 1966 3888 3890
39. X. Yang, Z. Guo, F. Sun, W. Li, A. Alfano, H. Shimelis, M. Chen, A.M. Brodie, H. Chen, Z. Xiao, T.D. Veenstra, and Y. Qiu Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells J. Biol. Chem. 286 2011 36152 36160
40. L. Zhang, F.X. Gu, J.M. Chan, A.Z. Wang, R.S. Langer, and O.C. Farokhzad Nanoparticles in medicine: therapeutic applications and developments Clin. Pharmacol. Ther. 83 2008 761 769
41. Y. Zhou, F.G. Gwadry, W.C. Reinhold, L.D. Miller, L.H. Smith, U. Scherf, E.T. Liu, K.W. Kohn, Y. Pommier, and J.N. Weinstein Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects Cancer Res. 62 2002 1688 1695